A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
November 12th, 2019
53.6K views
We describe a quantitative real-time in vitro cytolysis assay system to evaluate the potency of chimeric antigen receptor T cells targeting liquid and solid tumor cells. This protocol can be extended to assess other immune effector cells, as well as combination treatments.
Overview
This article presents a quantitative real-time in vitro cytolysis assay system designed to evaluate the potency of chimeric antigen receptor (CAR) T cells against both liquid and solid tumor cells. The methodology allows for the assessment of various immune effector cells and combination treatments.
Key Study Components
Area of Science
- Immunology
- Cancer Biology
- Cell Biology
Background
- Chimeric antigen receptor T cells are engineered to target specific cancer cells.
- Real-time monitoring of cell interactions provides insights into immune responses.
- The assay system can be adapted for various experimental conditions.
- Understanding T cell efficacy is crucial for developing effective cancer therapies.
Purpose of Study
- To establish a reliable assay for evaluating CAR T cell potency.
- To facilitate the screening of different immune effector cells.
- To assess the effectiveness of combination therapies in cancer treatment.
Methods Used
- Utilization of xCELLigence real-time cell analysis for monitoring cancer cell killing.
- Transfection of HEK293FT cells to produce lentivirus for CAR T cell generation.
- Flow cytometry for detecting CAR expression in T cells.
- Real-time impedance measurement to assess cytolysis potency over time.
Main Results
- Significant killing of target cancer cells by CAR T cells was observed.
- About 50% of CAR T cells expressed the CAR, indicating successful transduction.
- Different effector to target ratios were tested to evaluate efficacy.
- CD22-CAR T cells showed enhanced cytolytic activity compared to controls.
Conclusions
- The assay system effectively quantifies the potency of CAR T cells.
- This method can be adapted for various immune cell types and treatments.
- Real-time monitoring provides valuable data for optimizing cancer therapies.
Frequently Asked Questions
What is the main focus of this study?
The study focuses on developing a quantitative assay to evaluate CAR T cell potency against tumors.
How does the real-time cell analysis work?
It measures the impedance changes in cell cultures to monitor cell interactions and killing in real-time.
What types of cells can be assessed using this method?
The method can assess various immune effector cells and target both liquid and solid tumor cells.
What is the significance of CAR expression in T cells?
CAR expression is crucial for the T cells' ability to recognize and kill cancer cells effectively.
Can this assay be used for combination therapies?
Yes, the assay can be adapted to evaluate the effects of combination treatments on cancer cell killing.
Executive Industry Relevance
This real-time potency assay enables biopharma teams to quantitatively evaluate CAR T-cell efficacy against both hematological and solid tumor targets under label-free conditions. By providing continuous impedance-based readouts of tumor cell killing over multiple days, the method supports mechanistic de-risking of CAR constructs and informs go/no-go decisions in early discovery. The assay’s compatibility with low effector-to-target ratios and multiplexed construct screening enhances throughput for lead identification and portfolio triage.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses by linking costimulatory domains like GITR to enhanced cytotoxic activity against epithelial growth factor receptor-positive targets.
- Operational Value: Enables functional validation of CAR expression and potency in a single workflow, reducing ambiguity in target engagement.
- Predictive Value: Supports preclinical model selection by identifying constructs with superior tumor-killing kinetics prior to in vivo studies.
Screening & Assay Development
- Scientific Value: Generates quantitative, time-resolved cytolysis data that enable direct comparison of CAR constructs, effector cell types, or combination therapies.
- Operational Value: Standardizes potency assessment through label-free, real-time impedance measurements, improving reproducibility across teams and sites.
- Scalability: Permits simultaneous screening of numerous conditions in e-plate format, supporting assay readiness for downstream immunotherapy evaluation.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery-stage CAR-T optimization with preclinical validation by providing mechanistic insights into co-stimulatory domain function.
- Risk-Adjusted Advancement: Identifies non-performing constructs early (e.g., Mock CAR-T controls), reducing investment in low-potency candidates.
- Disease-Relevant Application: Demonstrates utility across liquid (Raji) and solid (pancreatic cancer) tumor models, supporting broad oncology pipeline relevance.
Pipeline & Workflow Integration
The assay fits within the discovery-to-preclinical continuum, enabling iterative design-test cycles for CAR-T optimization before committing to resource-intensive in vivo validation.
- Discovery Biology: Supports hypothesis testing of costimulatory signaling domains (e.g., GITR) and antigen-target pairs through real-time functional readouts.
- Screening: Delivers standardized, quantitative potency outputs that allow side-by-side comparison of CAR-T products under controlled effector-to-target ratios.
- Analytics: Provides impedance-based kinetic profiles and endpoint measurements that inform structure-activity relationships and combination therapy screening.
- Translational Research: Connects in vitro potency metrics to preclinical decision-making by highlighting constructs with tumor-specific activity (e.g., CD47-CAR-T in pancreatic cancer).
- Enterprise Reuse: Establishes a reusable platform for evaluating diverse immunotherapies, including bispecific engagers and checkpoint inhibitors, beyond CAR-T cells.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in CAR-T potency by linking molecular design (e.g., GITR domain) to functional tumor-killing outcomes.
- Operational Value: Enhances reproducibility and standardization of immuno-oncology assays through label-free, real-time impedance monitoring.
- Strategic Value: Improves capital efficiency by enabling early triage of CAR-T candidates based on quantitative cytolysis data.
- Portfolio Impact: Facilitates risk-adjusted prioritization of immunotherapy candidates through mechanistic de-risking of target engagement and effector function.
Implementation Considerations
- Requires expertise in lentiviral production, T-cell transduction, and flow cytometry for CAR validation.
- Dependent on xCELLigence or compatible real-time cell analysis instrumentation and e-plate consumables.
- Necessitates standardization of effector-to-target ratios and assay duration (e.g., 96-hour monitoring) across comparative studies.
- Adaptation to primary tumor cells or co-culture systems may require optimization of seeding density and medium conditions.
- Impedance signals from suspension effector cells (e.g., CAR-T) are minimal and do not interfere with target tumor cell adhesion-based readouts.
Biopharma FAQs
Why does real-time impedance monitoring matter for CAR-T potency assessment?
Real-time impedance monitoring enables continuous, label-free quantification of tumor cell killing over multiple days, providing kinetic insights into CAR-T efficacy that endpoint assays cannot capture. This supports mechanistic de-risking by revealing differences in cytolysis kinetics between constructs, such as enhanced activity observed with GITR costimulatory domains.
How does isolating effector-to-target ratio as an independent variable improve target validation?
Systematically varying effector-to-target ratios (e.g., 10:1) allows teams to assess CAR-T potency under controlled conditions, minimizing variability from cell concentration fluctuations. This isolation enables reliable comparison of constructs like CD22-CAR-T and Mock controls, supporting accurate target engagement and functional validation.
What quantitative dependent variable measurements does the xCELLigence assay enable?
The assay generates real-time impedance-based readouts (cell index) that reflect tumor cell adhesion and proliferation, with decreases indicating cytolysis. These quantitative measurements allow tracking of killing kinetics and endpoint analysis over 96 hours, enabling data-driven comparisons of CAR-T constructs and combination therapies.
Why are replication requirements critical for cross-functional collaboration in immunotherapy development?
Replication ensures that potency observations (e.g., CD47-CAR-T activity in pancreatic cancer cells) are consistent across experiments, reducing false positives and building confidence in translational relevance. Standardized protocols for lentivirus production, T-cell expansion, and assay setup enable hematology, oncology, and process teams to align on go/no-go criteria.
What statistical analysis capabilities are required before implementing this assay in a discovery pipeline?
Teams must be able to analyze time-series impedance data, calculate area under the curve or slope-based metrics for cytolysis rates, and apply appropriate statistical tests (e.g., t-tests, ANOVA) to compare conditions. This enables objective evaluation of constructs like GITR-containing CAR-Ts versus baseline designs, supporting predictive confidence in lead selection.
Chapters in this video
0:04
Title
0:30
Chimeric Antigen Receptor (CAR)-Encoding Lentivirus Generation
2:29
CAR T Cell Generation and Expansion
3:16
CAR Expression Detection
4:55
Real-Time Cytolysis Potency Assay
6:48
Results: Representative CAR T Cell Target Cell Killing Efficacy as Assessed by RTCA
8:05
Conclusion
